Journal of Parkinson s Disease · 2021 · 27 citations · 80 references
Life SciencesNeurologyNeuroscienceMolecular NeurobiologyMolecular NeuroscienceNeurodegenerationNeurodegenerative DiseasesNeurodegenerative DisordersParkinson DiseasePrion Protein MisfoldingProtein AggregationProtein Aggregation DisordersAlpha-synuclein AggregationAlpha-synuclein MisfoldingParkinson Disease PathologyPrion PathogenesisPrion-like PropagationPrion-like Protein SpreadingPrion-like SpreadingProtein Aggregates
BACKGROUND: Alpha-synuclein (αsyn) characterizes neurodegenerative diseases known as synucleinopathies. The phosphorylated form (psyn) is the primary component of protein aggregates known as Lewy bodies (LBs), which are the hallmark of diseases such as Parkinson's disease (PD). Synucleinopathies might spread in a prion-like fashion, leading to a progressive emergence of symptoms over time. αsyn pre-formed fibrils (PFFs) induce LB-like pathology in wild-type (WT) mice, but questions remain about their progressive spread and their associated effects on behavioral performance. OBJECTIVE: To characterize the behavioral, cognitive, and pathological long-term effects of LB-like pathology induced after bilateral motor cortex PFF injection in WT mice and to assess the ability of mouse αsyn-targeted antisense oligonucleotides (ASOs) to ameliorate those effects. METHODS: We induced LB-like pathology in the motor cortex and connected brain regions of male WT mice using PFFs. Three months post-PFF injection (mpi), we assessed behavioral and cognitive performance. We then delivered a targeted ASO via the ventricle and assessed behavioral and cognitive performance 5 weeks later, followed by pathological analysis. RESULTS: At 3 and 6 mpi, PFF-injected mice showed mild, progressive behavioral deficits. The ASO reduced total αsyn and psyn protein levels, and LB-like pathology, but was also associated with some deleterious off-target effects not involving lowering of αsyn, such as a decline in body weight and impairments in motor function. CONCLUSIONS: These results increase understanding of the progressive nature of the PFF model and support the therapeutic potential of ASOs, though more investigation into effects of ASO-mediated reduction in αsyn on brain function is needed.
80
Staging of brain pathology related to sporadic Parkinson’s disease
Heiko Braak, Kelly Del Tredici, Udo Rüb et al. · Neurobiology of Aging · 2002 · 10.8K citations
Medicine, Neurology, Neuroscience +13
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Mihael H. Polymeropoulos, Christian Lavedan, Elisabeth Leroy et al. · Science · 1997 · 8.2K citations
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
J.J. Zarranz, Juan Carlos Gómez‐Esteban, Elena Lezcano et al. · Annals of Neurology · 2003 · 2.7K citations
Life Sciences, Genetics, Neurology +17